Critical Mass With Law.com's Amanda Bronstad: Two Talc Trials Take Off Against Johnson & Johnson, Abbott Faces Another Trial Over Preterm Infant Formula

Why It Matters

These filings signal escalating liability exposure for major consumer‑product firms and underscore growing judicial scrutiny of class‑action strategies, affecting investors and corporate risk management.

Key Takeaways

• Two J&J talc trials start in Washington, Florida
• Abbott faces fourth NEC lawsuit over preterm formula
• Paraquat makers seek to block Parkinson’s disease claims
• Judge rejects Beasley Allen’s counsel delay request
• Experts dismissed in baby‑food autism/ADHD case

Pulse Analysis

The current surge in mass‑tort litigation reflects a broader shift toward aggressive plaintiff strategies against legacy consumer‑product giants. Recent filings against Johnson & Johnson’s talc and Abbott’s infant formula illustrate how plaintiffs are leveraging scientific studies and public health concerns to pursue multi‑billion‑dollar verdicts. Courts are increasingly scrutinizing counsel selection and expert credibility, as seen in the recent rulings on alternative counsel in the talc MDL and the dismissal of experts in the baby‑food autism case, tightening procedural safeguards for defendants.

Johnson & Johnson’s talc cases have become a bellwether for product‑liability risk management. The Dallas firm Dean O. Branham & Shirley, fresh off $966 million and $1.5 billion verdicts, now leads two new mesothelioma trials, potentially setting fresh precedent for compensation scales and discovery practices. These trials could pressure J&J to accelerate settlement talks or restructure its talc business, while also prompting other manufacturers to reassess internal testing and labeling protocols to mitigate future claims.

The Abbott preterm infant formula lawsuit adds another layer of complexity to the baby‑food sector, where regulatory agencies and hospitals are already vigilant about necrotizing enterocolitis. As the fourth NEC trial proceeds, manufacturers may face heightened scrutiny over formula composition and hospital procurement policies. Combined with the paraquat litigation aiming to preempt Parkinson’s disease claims, these developments underscore a legal environment where scientific evidence and consumer safety narratives increasingly drive litigation outcomes, influencing both market valuations and corporate compliance strategies.